Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-63.58 Insider Own6.23% Shs Outstand3.20M Perf Week3.39%
Market Cap1.69M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.00M Perf Month-33.68%
Income-13.28M PEG- EPS next Q- Inst Own0.86% Short Float1.81% Perf Quarter-72.27%
Sales0.00M P/S- EPS this Y- Inst Trans7.63% Short Ratio0.07 Perf Half Y-93.77%
Book/sh0.40 P/B1.32 EPS next Y- ROA-373.75% Short Interest0.05M Perf Year-99.53%
Cash/sh0.57 P/C0.93 EPS next 5Y- ROE-1021.38% 52W Range0.50 - 115.50 Perf YTD-80.41%
Dividend Est.- P/FCF- EPS past 5Y26.64% ROI-5128.57% 52W High-99.54% Beta-1.60
Dividend TTM- Quick Ratio1.09 Sales past 5Y-20.00% Gross Margin- 52W Low4.93% ATR (14)0.07
Dividend Ex-Date- Current Ratio1.09 EPS Y/Y TTM61.85% Oper. Margin0.00% RSI (14)31.29 Volatility7.27% 8.90%
Employees4 Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price2520.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q87.41% Payout- Rel Volume0.57 Prev Close0.52
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsApr 01 BMO Avg Volume745.39K Price0.53
SMA20-13.79% SMA50-33.82% SMA200-93.57% Trades Volume424,131 Change2.03%
Apr-16-24 08:35AM
Apr-08-24 08:35AM
Apr-01-24 07:35AM
Mar-28-24 09:00AM
Mar-14-24 08:45AM
08:30AM Loading…
Mar-04-24 08:30AM
Feb-02-24 08:55AM
Jan-26-24 08:05AM
Dec-06-23 01:47PM
Dec-05-23 09:05AM
Nov-27-23 08:35AM
Nov-15-23 08:05AM
Oct-31-23 08:45AM
Oct-19-23 08:45AM
10:00AM Loading…
Oct-18-23 10:00AM
Oct-17-23 08:35AM
Oct-11-23 09:05AM
Oct-05-23 08:45AM
Sep-29-23 09:00AM
Sep-06-23 09:05AM
Sep-01-23 09:15AM
Aug-29-23 11:06AM
Aug-25-23 09:00AM
Aug-23-23 09:00AM
Aug-16-23 12:00PM
Aug-14-23 08:05AM
Aug-07-23 08:35AM
Aug-03-23 08:30AM
Jul-26-23 11:15AM
09:00AM Loading…
Jul-24-23 09:00AM
Jul-05-23 08:45AM
Jun-27-23 08:45AM
Jun-15-23 08:45AM
Jun-13-23 08:35AM
May-22-23 08:45AM
Apr-27-23 09:05AM
Apr-25-23 08:45AM
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.